Zobrazeno 1 - 10
of 159
pro vyhledávání: '"R, Ortega López"'
Autor:
Zink, Maria1 (AUTHOR) zink.maria@baua.bund.de, Pischke, Frederike2 (AUTHOR), Wendsche, Johannes1 (AUTHOR), Melzer, Marlen1 (AUTHOR)
Publikováno v:
BMC Nursing. 9/27/2024, Vol. 23 Issue 1, p1-18. 18p.
Autor:
Tchouaket, Eric Nguemeleu1 (AUTHOR) eric.tchouaket@uqo.ca, Kruglova, Katya1 (AUTHOR), Létourneau, Josiane1 (AUTHOR), Bélanger, Emilie1 (AUTHOR), Robins, Stephanie1 (AUTHOR), Jubinville, Maripier1 (AUTHOR), El-Mousawi, Fatima1 (AUTHOR), Shen, Shiyang2 (AUTHOR), Beogo, Idrissa3 (AUTHOR), Sia, Drissa1 (AUTHOR)
Publikováno v:
BMC Health Services Research. 8/7/2024, Vol. 24 Issue 1, p1-48. 48p.
Autor:
Minić, Simeon1 (AUTHOR) sminic@chem.bg.ac.rs, Gligorijević, Nikola2 (AUTHOR), Veličković, Luka1 (AUTHOR), Nikolić, Milan1 (AUTHOR)
Publikováno v:
International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 13, p7187. 23p.
Autor:
Zvereva, Marina1 (AUTHOR) mlesnichaya@mail.ru
Publikováno v:
Polymers (20734360). Jun2024, Vol. 16 Issue 11, p1482. 20p.
Publikováno v:
BMC Palliative Care. 5/23/2024, Vol. 23 Issue 1, p1-13. 13p.
Autor:
A. Salmerón-García, N. Navas Iglesias, J. Cabeza Barrera, A. Lario Simon, M.V. Longobardo Polanco, R. Ortega López, L.F. Capitán Vallvey
Publikováno v:
European Journal of Hospital Pharmacy. 19:83.2-83
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86c454e19fc2f8f7ee8c30391fe50a37
https://doi.org/10.1136/ejhpharm-2012-000074.83b
https://doi.org/10.1136/ejhpharm-2012-000074.83b
Autor:
N Navas Iglesias, V. Longobardo Polanco, Antonio Salmerón-García, Luis Fermín Capitán-Vallvey, A. Lario Simon, J Cabeza Barrera, R. Ortega López
Publikováno v:
European Journal of Hospital Pharmacy. 19:152.1-152
Background The active substance of MabThera is rituximab. It is a genetically engineered chimeric mouse/human monoclonal antibody which binds specifically to the transmembrane antigen CD20. It is currently indicated for the treatment of several folli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7f6dc10a3a7a1efbc8705b06a1ed9ff
https://doi.org/10.1136/ejhpharm-2012-000074.178
https://doi.org/10.1136/ejhpharm-2012-000074.178
Autor:
R. Ortega López, L.F. Capitán Vallvey, N Navas Iglesias, Antonio Salmerón-García, M.V. Longobardo Polanco, A. Lario Simon, J. Cabeza Barrera
Publikováno v:
European Journal of Hospital Pharmacy. 19:149.1-149
Background The active substance of Remicade is infliximab. It is a chimeric human-murine monoclonal antibody directed against tumour necrosis factor α (TNFα), manufactured from a recombinant cell line. Remicade is presented as powder for concentrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fba099914ed12f0e59132dd71cd62d7
https://doi.org/10.1136/ejhpharm-2012-000074.170
https://doi.org/10.1136/ejhpharm-2012-000074.170
Autor:
L.F. Capitán Vallvey, S Ruiz Fuentes, J. Cabeza Barrera, N Navas Iglesias, R. Ortega López, Antonio Salmerón-García
Publikováno v:
European Journal of Hospital Pharmacy. 19:149.3-150
Background In patients with infection related to catheter (IRC) is needed to consider several aspects that will lead both the managing and treatment of them. When the retention of the catheter is advisable it is necessary to apply technologies of sea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b02293fc0fec3eebcdbb46c950ef82fe
https://doi.org/10.1136/ejhpharm-2012-000074.172
https://doi.org/10.1136/ejhpharm-2012-000074.172
Autor:
Gill, Ashlinder1 (AUTHOR) gilla89@mcmaster.ca, Meadows, Lynn2 (AUTHOR), Ashbourne, Jessica3 (AUTHOR), Kaasalainen, Sharon4 (AUTHOR), Shamon, Sandy3,5 (AUTHOR), Pereira, José3,6 (AUTHOR)
Publikováno v:
Palliative Care & Social Practice. 3/5/2024, p1-10. 10p.